Insights Into Testing Protocols and Treatment Pathways for NTRK Fusion-Positive Cancers

Perspectives of community physicians from across the US on optimal integration and side effect management of novel therapies

September 14, 2021

Faculty Chair

Lee Schwartzberg, MD, FACP

West Cancer Center, Memphis, TN

More Information

  • Virtual series

Example Report

Start discovering the insights

View Report


  • NTRK Gene Fusions as Oncogenic Drivers 
  • Treatment of Thyroid/Salivary Gland Cancers 
  • Consensus Pathway Discussion: Thyroid/Salivary Gland Cancers  
  • Treatment of Lung Cancer 
  • Consensus Pathway Discussion: Lung Cancer 


  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprised 10–15 medical oncologists

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.